BioSpace News Archive

Integra LifeSciences Holdings Corporation is pleased to announce that following a successful Q1 2024 U.S. relaunch of its CereLink® ICP Monitoring System, the innovative product will be featured at the upcoming AANS Annual Scientific Meeting from May 3 through 6, 2024, in Chicago, Illinois.

Mirion, a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, announced results for the first quarter ended March 31, 2024.

TG Therapeutics, Inc., announced that a conference call will be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ET to discuss results for the first quarter of 2024 and provide a business outlook for 2024.

ICON plc announced the pricing of a USD 2 billion SEC-registered bond offering, consisting of $750,000,000 5.809% Senior Secured Notes due 2027, $750,000,000 5.849% Senior Secured Notes due 2029 and $500,000,000 6.000% Senior Secured Notes due 2034.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved INGREZZA® SPRINKLE (valbenazine) capsules, a new oral granules formulation of INGREZZA® (valbenazine) capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with Huntington’s disease.

Merrimack Pharmaceuticals, Inc. announced that it has filed notice with NASDAQ of the Company’s intent to delist its securities from NASDAQ, subject to receipt of stockholder approval of the Plan of Dissolution at the Special Meeting of Stockholders of Merrimack scheduled to be held on Friday, May 10, 2024.

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, announced it granted an inducement award on April 30, 2024.

Emergent BioSolutions Inc. announced that it has entered into a “Consent, Waiver and Seventh Amendment” to its existing credit facility.

MedMira Inc. is pleased to announce the expansion of their commercialisation team by welcoming Ms. Rene Bell to the position of Vice President of Business Development.

Ansa Biotechnologies, Inc. today announced its speaker lineup for presentations at the upcoming Global Synthetic Biology (SynBioBeta) Conference in San Jose, Calif., from May 6-9, 2024.